In addition, diabetic ketoacidosis has been reported in patients with T1DM who were treated off-label with an SGLT2 inhibitor in daily clinical practice [35, 36].Therefore application of SGLT2 inhibitors for T1DM still remains to be addressed. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.